The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Optimize Gout Management with the Latest Evidence-Based Guidance

Optimize Gout Management with the Latest Evidence-Based Guidance

November 17, 2020 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2020—In May 2020, the ACR published its updated guideline for the management of gout.1 It followed on the heels of a 2017 gout guideline published by the American College of Physicians.2 Although the guidelines provide similar recommendations on the treatment of acute gout, they differ importantly in the use of uric acid-lowering therapy for long-term management of gout.hand-with-gout image In a session titled Evidence-Based Guidance for Optimizing Gout Management, Robert Terkeltaub, MD, chief of rheumatology at the VA Medical Center San Diego, professor of medicine in the Division of Rheumatology, Allergy and Immunology at the University of California, San Diego, and president of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN), discussed these differences and highlighted the evidence that continues to support the ACR recommendations on uric acid-lowering and treat-to-target strategies for managing chronic or tophaceous gout.

You Might Also Like
  • ACR Releases Guidelines for Gout Management
  • Treatment, Management Options for Difficult-to-Control Gout
  • FAST Results for Febuxostat Safety in Patients with Gout
Also By This Author
  • Sedentary Lifestyle Linked to Reduced Quality of Life in People with Knee OA

Calling the new evidence weighed by the 2020 ACR updated guidelines “robust,” Dr. Terkeltaub provided an assessment of the new data supporting the strong benefits of lowering uric acid levels on reducing joint structural effects and damage (e.g., synovitis and erosions), reducing the uric acid burden (e.g., uric crystal deposits in tissue) and managing symptoms (e.g., acute flares). “These are all significant and impactful benefits that justify a uric acid-lowering approach in more patients, as well as a treat-to-target strategy,” he said. Table 1 (below) highlights the results of the key evidence he discussed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Some unknowns remain: One important question not addressed in the guideline is how to more quickly prevent or limit synovitis and joint damage, including erosions. Another is what the impact of achieving targeted uric acid levels is on the whole patient. Dr. Terkeltaub discussed remaining gaps in the clinical care of gout and emphasized the important role of pharmacogenetics to arrive at a more precise way to treat patients (see Table 2, bottom). He also provided a graphic showing the heterogenous elements of gout that need attention to provide more precise and personalized management of gout (see Figure 1).

gout elements graphic

Figure 1. Click to enlarge.

Treat the Whole Person
Dr. Terkeltaub believes answers to these questions will be forthcoming, particularly given the work being done in providing good molecular pharmacogenomics. Citing the use of the HLA-B*5801 gene test to predict severe allopurinol hypersensitivity syndrome to identify patients to whom allopurinol should not be given, he underscored the growing interest in, and understanding of, the ABC transporter gene ABCG2 and whether it and its variant, Q141K ABCG2, may offer similar benefits for gout management.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: ACR Convergence, Conditions, Crystal Arthritis, Guidelines, Meeting Reports Tagged With: ACR Convergence 2020, ACR Convergence 2020 – Gout, Gout

You Might Also Like:
  • ACR Releases Guidelines for Gout Management
  • Treatment, Management Options for Difficult-to-Control Gout
  • FAST Results for Febuxostat Safety in Patients with Gout
  • Dr. Ethan Craig Picks His Favorite Gout Abstracts from ACR Convergence 2020

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)